SCHEMBL2772290

SCHEMBL2772290

CCNc1cc(Cl)nc(NCC)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
ESR1 P03372 3/20 0.41
CDK9 P50750 2/20 0.40
CDK5 Q00535 2/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PAK4 O96013 1/20 0.40
ABL1 P00519 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
IGF1R P08069 1/20 0.40
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
FLT1 P17948 1/20 0.40
LTK P29376 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7834331 0.87 LMNA (0.60) LMNAMAPTKMT2ACDK9CDK5
SCHEMBL10093922 0.82 ESR1 (0.50) LMNAMAPTKMT2AESR1GSK3B
SCHEMBL11652757 0.81 LMNA (0.42) LMNAMAPTKMT2ACDK9CDK5
SCHEMBL9105998 0.81 ESR1 (0.58) LMNAKMT2AESR1CDK9CDK5
SCHEMBL8349356 0.80 KMT2A (0.54) LMNAMAPTKMT2AGAAPOLB
SCHEMBL9592998 0.80 GAA (0.46) LMNAMAPTKMT2AESR1CDK9
SCHEMBL6106890 0.78 LMNA (0.50) LMNAMAPTKMT2ACDK9CDK5
SCHEMBL1318375 0.78 CYP2D6 (0.64) LMNAMAPTKMT2ACDK9CDK5
SCHEMBL6107053 0.78 ADORA1 (0.41) LMNAMAPTKMT2AKDRMAPK8
SCHEMBL16608746 0.78 LMNA (0.50) LMNAMAPTKMT2AESR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-06-03 US disclosed
EP-2152675-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2010-02-17 EP disclosed
WO-2008152223-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE IPSEN PHARMA S.A.S. (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137275-A1 TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE CDC25A, CDC25B, CDC25C LMNA 4708/4885MAPT 4555/4885KMT2A 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.